GSK plc Reports Transaction in Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Jul 21, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Jul 21, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-transaction, sec-filing, foreign-private-issuer
TL;DR
GSK plc filed a 6-K on 7/21/25 for a transaction in its own shares.
AI Summary
GSK plc announced on July 21, 2025, that it has completed a transaction involving its own shares. The filing, a Form 6-K, is a report of a foreign private issuer and indicates GSK plc's ongoing compliance with SEC regulations. The company's principal executive office is located at 79 New Oxford Street, London, WC1A 1DG.
Why It Matters
This filing provides transparency to investors regarding GSK's share activities, which can impact stock valuation and corporate governance.
Risk Assessment
Risk Level: low — This is a routine disclosure filing by a large, established company and does not indicate any immediate financial distress or significant operational changes.
Key Players & Entities
- GSK plc (company) — Registrant
- 79 New Oxford Street, London, WC1A 1DG (location) — Principal executive office
- July 2025 (date) — Reporting period
- 20250721 (date) — Filing date
FAQ
What type of SEC filing is this report from GSK plc?
This report is a Form 6-K, which is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
What is the primary subject of this 6-K filing?
The primary subject of this filing is a 'Transaction in own shares' by GSK plc.
When was this Form 6-K filed with the SEC?
The filing was made on July 21, 2025.
Where is GSK plc's principal executive office located?
GSK plc's principal executive office is located at 79 New Oxford Street, London, WC1A 1DG.
Does GSK plc file annual reports under Form 20-F or Form 40-F?
GSK plc indicates it files annual reports under cover of Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on July 21, 2025 regarding GSK plc (GLAXF).